Drug Trial News

RSS

GW to participate in a clinical trial for investigational COVID-19 vaccine

The George Washington University today announced that it will participate in a clinical trial for an investigational COVID-19 vaccine.

27 Jul 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020

Brigham to play two key roles in phase 3 trial of COVID-19 vaccine candidate

A vaccine candidate for preventing COVID-19 is advancing to a 30,000-participant phase 3 trial that begins today, and Brigham and Women's Hospital will play two key roles in the trial's next phase.

27 Jul 2020

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.

27 Jul 2020

National clinical trial to test potential vaccine against SARS-CoV-2

UC San Diego Health and the Altman Clinical and Translational Research Institute, part of UC San Diego School of Medicine, will be sites for an accelerated national clinical trial to assess the efficacy and immunogenicity of a vaccine intended to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

25 Jul 2020

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

Researchers have shown that hydroxychloroquine interferes with only one redundant pathway that activates the SARS-CoV-2 spike protein.

24 Jul 2020

New article sheds light on challenges faced by vaccine developers

With the global pandemic still in full swing, scientists are working to develop a vaccine in record time. While everyone wants an effective vaccine, they don't all agree on how to get there and what "effective" really means.

23 Jul 2020

Researchers develop new device for rehabilitation of stroke patients

A research group has developed a new, lightweight and motor-less device that can be easily attached to an ankle support device - otherwise known as an ankle foot orthosis (AFO).

23 Jul 2020

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority.

22 Jul 2020

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

Drug discovery pipeline to exploit transcription factors for cancer therapy

Cancer is a leading cause of death and one of the most complex challenges to modern medicine. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up company QUANTRO Therapeutics strives to radically change the precision and scope of cell-based drug screening.

21 Jul 2020

UC Davis Health evaluates new antibody cocktail as a possible treatment for COVID-19

Timothy Albertson, chair of internal medicine and specialist in pulmonary and critical care, is leading efforts at UC Davis Health to test a new antibody cocktail (REGN-COV2) as a prevention and treatment for COVID-19.

20 Jul 2020

China's Ad5 vectored COVID-19 vaccine safe and induces immune response

A phase 2 trial of an Ad5 vectored COVID-19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research published in The Lancet.

20 Jul 2020

Oxford University and AstraZeneca vaccine against SARS-CoV-2 safe and induces immune response

Promising early stage results from a phase 1/2 clinical trial of the UK's vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) are published today in The Lancet.

20 Jul 2020

Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today

The coronavirus pandemic is still rapidly spreading across the globe, infecting more than 14.44 million people. With more than 188 countries and territories affected, scientists are racing to develop a vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).

19 Jul 2020

Hydroxychloroquine is not indicated for COVID-19 under any circumstances

The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).

19 Jul 2020

Sanders-Brown researchers screen first participant in drug study to prevent early Alzheimer's

Researchers at the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study.

17 Jul 2020

Avicenna.AI secures FDA clearance for its CINA Head neurovascular imaging artificial intelligence tool

Medical imaging AI specialist Avicenna.AI today announced it has received 510(k) clearance from the US Food and Drug Administration for its CINA Head triage AI solution for neurovascular emergencies.

17 Jul 2020

Compelling study shows heparin may protect against COVID-19

A compelling new study conducted by an international team of researchers has demonstrated that the widely used blood-thinning medication - heparin - can block infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

16 Jul 2020

Previous
1
...
72
73
74
75
76
77
78
...
1143
Next

Drug Trial News

GW to participate in a clinical trial for investigational COVID-19 vaccine

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Brigham to play two key roles in phase 3 trial of COVID-19 vaccine candidate

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

National clinical trial to test potential vaccine against SARS-CoV-2

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

New article sheds light on challenges faced by vaccine developers

Researchers develop new device for rehabilitation of stroke patients

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

Drug discovery pipeline to exploit transcription factors for cancer therapy

UC Davis Health evaluates new antibody cocktail as a possible treatment for COVID-19

China's Ad5 vectored COVID-19 vaccine safe and induces immune response

Oxford University and AstraZeneca vaccine against SARS-CoV-2 safe and induces immune response

Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today

Hydroxychloroquine is not indicated for COVID-19 under any circumstances

Sanders-Brown researchers screen first participant in drug study to prevent early Alzheimer's

Avicenna.AI secures FDA clearance for its CINA Head neurovascular imaging artificial intelligence tool

Compelling study shows heparin may protect against COVID-19

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News